Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants
(2019) In European Urology 75(1). p.18-22- Abstract
Molecular subtyping may inform on prognosis and treatment response in bladder cancer. However, intratumoral molecular heterogeneity is not well studied in this disease and could complicate efforts to use molecular subtyping to guide patient management. To investigate intratumoral heterogeneity in bladder cancer, we examined molecular subtypes in a consecutive, retrospective cystectomy series of histologic variant bladder cancers and conventional urothelial carcinomas co-occurring with them. Molecular subtypes were assigned as per the approach reported by Lund University, an approach that incorporates cell cycle alterations and markers of differentiation, to give the urothelial-like, genomically unstable, basal-squamous,... (More)
Molecular subtyping may inform on prognosis and treatment response in bladder cancer. However, intratumoral molecular heterogeneity is not well studied in this disease and could complicate efforts to use molecular subtyping to guide patient management. To investigate intratumoral heterogeneity in bladder cancer, we examined molecular subtypes in a consecutive, retrospective cystectomy series of histologic variant bladder cancers and conventional urothelial carcinomas co-occurring with them. Molecular subtypes were assigned as per the approach reported by Lund University, an approach that incorporates cell cycle alterations and markers of differentiation, to give the urothelial-like, genomically unstable, basal-squamous, mesenchymal-like, and neuroendocrine-like subtypes. The majority (93%) of tumors were classified as urothelial like, genomically unstable, or basal squamous. Among patients with more than one tumor histology, 39% demonstrated molecular heterogeneity among the different tumor histologies. This was greatest for the basal-squamous subtype, 78% of which co-occurred with either urothelial-like or genomically unstable carcinoma (among cases with multiple histologies). In contrast, there was no co-occurrence of urothelial-like and genomically unstable carcinoma in the same patient. The findings indicate that bladder cancer is often molecularly heterogeneous, particularly in the basal-squamous subtype. This raises the concern for sampling error in laboratory tests that guide therapy based on molecular subtyping. Patient summary: In this report, we investigated molecular diversity among different areas from the same tumor in patients with bladder cancer. We found that different areas from the same tumor are often molecularly different. We conclude that this biological diversity must be taken into account when interpreting clinical molecular tests performed on bladder cancer samples. In bladder cancer, molecular subtype commonly differs between histologically distinct areas from the same tumor, most commonly in those with a component of the basal-squamous subtype. This suggests concern for sampling error in molecular tests based on molecular subtyping.
(Less)
- author
- Warrick, Joshua I. ; Sjödahl, Gottfrid LU ; Kaag, Matthew ; Raman, Jay D. ; Merrill, Suzanne ; Shuman, Lauren ; Chen, Guoli ; Walter, Vonn and DeGraff, David J.
- organization
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Histologic variant, Intratumoral heterogeneity, Molecular subtype
- in
- European Urology
- volume
- 75
- issue
- 1
- pages
- 18 - 22
- publisher
- Elsevier
- external identifiers
-
- scopus:85053884922
- pmid:30266310
- ISSN
- 0302-2838
- DOI
- 10.1016/j.eururo.2018.09.003
- language
- English
- LU publication?
- yes
- id
- a16ce6f2-05fc-44ad-b927-14997ddf23fd
- date added to LUP
- 2018-10-23 08:12:14
- date last changed
- 2024-06-11 21:21:08
@article{a16ce6f2-05fc-44ad-b927-14997ddf23fd,
abstract = {{<p>Molecular subtyping may inform on prognosis and treatment response in bladder cancer. However, intratumoral molecular heterogeneity is not well studied in this disease and could complicate efforts to use molecular subtyping to guide patient management. To investigate intratumoral heterogeneity in bladder cancer, we examined molecular subtypes in a consecutive, retrospective cystectomy series of histologic variant bladder cancers and conventional urothelial carcinomas co-occurring with them. Molecular subtypes were assigned as per the approach reported by Lund University, an approach that incorporates cell cycle alterations and markers of differentiation, to give the urothelial-like, genomically unstable, basal-squamous, mesenchymal-like, and neuroendocrine-like subtypes. The majority (93%) of tumors were classified as urothelial like, genomically unstable, or basal squamous. Among patients with more than one tumor histology, 39% demonstrated molecular heterogeneity among the different tumor histologies. This was greatest for the basal-squamous subtype, 78% of which co-occurred with either urothelial-like or genomically unstable carcinoma (among cases with multiple histologies). In contrast, there was no co-occurrence of urothelial-like and genomically unstable carcinoma in the same patient. The findings indicate that bladder cancer is often molecularly heterogeneous, particularly in the basal-squamous subtype. This raises the concern for sampling error in laboratory tests that guide therapy based on molecular subtyping. Patient summary: In this report, we investigated molecular diversity among different areas from the same tumor in patients with bladder cancer. We found that different areas from the same tumor are often molecularly different. We conclude that this biological diversity must be taken into account when interpreting clinical molecular tests performed on bladder cancer samples. In bladder cancer, molecular subtype commonly differs between histologically distinct areas from the same tumor, most commonly in those with a component of the basal-squamous subtype. This suggests concern for sampling error in molecular tests based on molecular subtyping.</p>}},
author = {{Warrick, Joshua I. and Sjödahl, Gottfrid and Kaag, Matthew and Raman, Jay D. and Merrill, Suzanne and Shuman, Lauren and Chen, Guoli and Walter, Vonn and DeGraff, David J.}},
issn = {{0302-2838}},
keywords = {{Histologic variant; Intratumoral heterogeneity; Molecular subtype}},
language = {{eng}},
number = {{1}},
pages = {{18--22}},
publisher = {{Elsevier}},
series = {{European Urology}},
title = {{Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants}},
url = {{http://dx.doi.org/10.1016/j.eururo.2018.09.003}},
doi = {{10.1016/j.eururo.2018.09.003}},
volume = {{75}},
year = {{2019}},
}